secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-06-10T11:32:05+00:00
Accession:  0001193125-26-264916
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Therapeutics reports positive clinical data for CLN-978 and velinotamig in autoimmune diseases
--------------------------------------------------------------------------------

- CLN-978 achieved DAS28-ESR remission in a rituximab-refractory RA patient, reducing score from 4.0 to 2.2 at week 4.
- First three SLE patients on CLN-978 multi-dose showed safety consistent with EULAR 2026 data; rapid proteinuria improvement supports lupus nephritis trial.
- Velinotamig (BCMA TCE) induced complete renal responses in two SLE patients; SLEDAI-2K scores dropped to 0 and 2 at week 8.
- Cullinan plans Phase 2a expansion for CLN-978 in lupus nephritis in early 2027 and Phase 1/2a for velinotamig in autoimmune cytopenias in Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/0001193125-26-264916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526264916/cgem-20260610.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-264916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer